The Steve Jackson Laboratory Website
Transformative discoveries in genome and cellular integrity


Lab Announcements and Industry News

AZ moves closer to Lynparza filing in breast cancer

AZ have announced that they are closer to Lynparza (olaparib) being licensed for the treatment of breast cancer. Lynparza provided a statistically-significant improvement in progression-free survival compared to chemotherapy. This is the first positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer.

Kate Dry
Specific Roles of XRCC4 Paralogs PAXX and XLF during V(D)J Recombination

A new paper, published in Cell Reports, demonstrates that PAXX and XLF (paralogs of the nonhomologous endjoining factor XRCC4) have distinct roles during V(D)J recombination. V(D)J recombination is the process by which T cells and B cells randomly assemble different gene segments – known as variable (V), diversity (D) and joining (J) genes – in order to generate unique receptors (known as antigen receptors) that can collectively recognize many different types of molecule. PAXX and XLF are required to join broken DNA ends generated during antigen receptor gene assembly. This work was the result of a collaboration between our lab and that of Ludovic Deriano at the Pasteur Institute.

Michael Lakeland
How cancer cells may divide and spread

Postdoc Christine Schmidt is co-corresponding author on a paper in ACS Nano. In this study the authors have used rolled-up nanomembranes to study how 3D spatial confinement affects the way single cells grow and divide.

Kate Dry
Inaugural Impact Award presented to Steve Jackson

Steve has won the University of Cambridge Vice Chancellor's inaugural Impact Award for the School of Biological Sciences, in recognition of his work on the DNA damage response, leading to the development of PARP inhibitors, a new class of anti-cancer drugs.

Kate Dry